000325670 Stock Overview
Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €24.40 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 0.24 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | 0% |
| 5 Year Change | 0.21% |
| Change since IPO | -14.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 000325670 | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 0% | 3.3% | -1.7% |
| 1Y | 0% | 120.2% | 11.0% |
Return vs Industry: 000325670 underperformed the Swiss Biotechs industry which returned 118.3% over the past year.
Return vs Market: 000325670 underperformed the Swiss Market which returned 11% over the past year.
Price Volatility
| 000325670 volatility | |
|---|---|
| 000325670 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in CH Market | 7.1% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: 000325670's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine 000325670's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,464 | Peter Janssen | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.
Biotest Aktiengesellschaft Fundamentals Summary
| 000325670 fundamental statistics | |
|---|---|
| Market cap | CHF 1.28b |
| Earnings (TTM) | CHF 155.10m |
| Revenue (TTM) | CHF 737.10m |
6.5x
P/E Ratio1.4x
P/S RatioIs 000325670 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000325670 income statement (TTM) | |
|---|---|
| Revenue | €781.30m |
| Cost of Revenue | €431.80m |
| Gross Profit | €349.50m |
| Other Expenses | €185.10m |
| Earnings | €164.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | 4.15 |
| Gross Margin | 44.73% |
| Net Profit Margin | 21.04% |
| Debt/Equity Ratio | 105.8% |
How did 000325670 perform over the long term?
See historical performance and comparison